Bachisio Ziccheddu

Bachisio Ziccheddu

Auto-generated profile, based on publicly available information

Bachisio Ziccheddu

Sheila and David Fuente Cancer Biology Graduate Program, University of Miami Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
FMFrancesco Maura
Francesco Maura
BZBachisio Ziccheddu
Bachisio Ziccheddu
JXJenny Z. Xiang
Jenny Z. Xiang
BBBhavneet Bhinder
Bhavneet Bhinder
JRJoel Rosiene
Joel Rosiene
LGLisa Giulino-Roth
Lisa Giulino-Roth
The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells in classic Hodgkin lymphoma (cHL) limits the ability to study the genomics of cHL. To circumvent this, our group has previously optimized fluorescence-activated cell sorting to purify HRS cells. Using this approach, we now report the whole-genome sequencing landscape of HRS cells and reconstruct the chronology and likely etiology of pathogenic events leading to cHL. We identified alterations in driver genes not previously described in cHL, APOBEC mutational activity, and the presence of complex structural variants including chromothripsis. We found that high ploidy in cHL is often acquired through multiple, independent chromosomal gains events including whole-genome duplication. Evolutionary timing analyses revealed that structural variants enriched for RAG motifs, driver mutations in B2M, BCL7A, GNA13, and PTPN1, and the onset of AID-driven mutagenesis usually preceded large chromosomal gains. This study provides a temporal reconstruction of cHL pathogenesis. Significance: Previous studies in cHL were limited to coding sequences and therefore not able to comprehensively decipher the tumor complexity. Here, leveraging cHL whole-genome characterization, we identify driver events and reconstruct the tumor evolution, finding that structural variants, driver mutations, and AID mutagenesis precede chromosomal gains. This article is highlighted in the In This Issue feature, p. 171

23 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
DKDickran Kazandjian
Dickran Kazandjian
BDBenjamin Diamond
Benjamin Diamond
MPMarios Papadimitriou
Marios Papadimitriou
EHElizabeth Hill
Elizabeth Hill
RSRomanos Sklavenitis-Pistofidis
Romanos Sklavenitis-Pistofidis
OLOla Landgren
Ola Landgren
Purpose: Early intervention for high-risk smoldering multiple myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to the treatment of less complex, susceptible disease or inaccuracy in clinical definition of cases entered. Experimental Design: In this study, we interrogated whole-genome and whole-exome sequencing for 54 patients across two HR-SMM interventional studies (NCT01572480 and NCT02279394). Results: We reveal that the genomic landscape of treated HR-SMM is generally simple as compared with newly diagnosed multiple myeloma counterparts with less inactivation of tumor suppressor genes, RAS pathway mutations, MYC disruption, and APOBEC contribution. The absence of these events parallels that of indolent precursor conditions, possibly explaining overall excellent outcomes. However, some patients harboring genomic complexity fail to sustain response and experience resistant, progressive disease. Overall, clinical risk scores do not effectively discriminate between genomically indolent and aggressive disease. Conclusions: Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy. See related commentary by Weinhold and Rasche, p. 4263

29 June 2020 in HemaSphere
Verified
Journal Article
Open access
MMMartina Manzoni
Martina Manzoni
APAlessandra Pompa
Alessandra Pompa
SFSonia Fabris
Sonia Fabris
FPFrancesca Pelizzoni
Francesca Pelizzoni
GCGabriella Ciceri
Gabriella Ciceri
MLMarta Lionetti
Marta Lionetti
Supplemental Digital Content is available in the text

4 September 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
MPMarios Papadimitriou
Marios Papadimitriou
SASungwoo Ahn
Sungwoo Ahn
BDBenjamin T. Diamond
Benjamin T. Diamond
HLHolly Lee
Holly Lee
JMJohn B. McIntyre
John B. McIntyre
FMFrancesco Maura
Francesco Maura
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532

22 May 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
BDBenjamin Diamond
Benjamin Diamond
DCDhanvantri Chahar
Dhanvantri Chahar
MJMichael D. Jain
Michael D. Jain
APAlexandra M. Poos
Alexandra M. Poos
MDMichael A. Durante
Michael A. Durante
FMFrancesco Maura
Francesco Maura
Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. In this study, we interrogated 580 whole-genome sequence (WGS) samples from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose–response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode, we demonstrate that a single RT-surviving cell may seed distant relapse. Significance: RT and the ID8 indel signature are related, but their genomic impact on hematologic malignancies is unclear. Leveraging WGS, we linked ID8 to both RT and mutagenic chemotherapy and validated that platinum can induce ID8. We used ID8 as a genomic barcode to reveal that RT-resistant cells may seed systemic relapse.

8 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MCMonika Chojnacka
Monika Chojnacka
BDBenjamin Diamond
Benjamin Diamond
BZBachisio Ziccheddu
Bachisio Ziccheddu
EREven Rustad
Even Rustad
KMKylee Maclachlan
Kylee Maclachlan
FMFrancesco Maura
Francesco Maura
Purpose: Whole-genome sequencing (WGS) of patients with newly diagnosed multiple myeloma (NDMM) has shown recurrent structural variant (SV) involvement in distinct regions of the genome (i.e., hotspots) and causing recurrent copy-number alterations. Together with canonical immunoglobulin translocations, these SVs are recognized as “recurrent SVs.” More than half of SVs were not involved in recurrent events. The significance of these “rare SVs” has not been previously examined. Experimental Design: In this study, we utilize 752 WGS and 591 RNA sequencing data from patients with NDMM to determine the role of rare SVs in myeloma pathogenesis. Results: Ninety-four percent of patients harbored at least one rare SV event. Rare SVs showed an SV class-specific enrichment within genes and superenhancers associated with outlier gene expression. Furthermore, known myeloma driver genes recurrently impacted by point mutations were dysregulated by rare SVs. Conclusions: Overall, we demonstrate the association of rare SVs with aberrant gene expression supporting a potential driver role in myeloma pathogenesis.